CN106267151A - Irrigation of lacrimal passage liquid is used in a kind of children's's dacryocystisis nursing - Google Patents
Irrigation of lacrimal passage liquid is used in a kind of children's's dacryocystisis nursing Download PDFInfo
- Publication number
- CN106267151A CN106267151A CN201610703829.7A CN201610703829A CN106267151A CN 106267151 A CN106267151 A CN 106267151A CN 201610703829 A CN201610703829 A CN 201610703829A CN 106267151 A CN106267151 A CN 106267151A
- Authority
- CN
- China
- Prior art keywords
- dacryocystisis
- children
- nursing
- irrigation
- lacrimal passage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a kind of children's's dacryocystisis nursing irrigation of lacrimal passage liquid, including the component of following mass percent: 0.01 0.04% laevo-ornidazole, 0.1 0.5% antibacterial peptide, 0.01 0.03% L-Borneol, 0.05 0.1% aescine, 0.02 0.2% obacunone, 0.02 0.05% allantoin, 0.03 0.08% naringenin, 0.005 0.1% shikimic acid, 0.003 0.1% cryptoxanthine, 0.01 0.1% vitamin A, 0.03 0.06% surfactant, surplus are water for injection.Children's's dacryocystisis nursing irrigation of lacrimal passage liquid phase of the present invention is for existing normal saline flushing liquid; there is antimicrobial antiphlogistic effect; enable in particular to control the infection caused by anaerobe; promote the postoperative recovery of probing of lacrimal passages; neural activity can be protected, to safeguarding that machine vision health has certain effect simultaneously.
Description
Technical field
The present invention relates to dacryocystisis nursing practical technique field, be specifically related to a kind of children's's dacryocystisis nursing lacrimal passage and rush
Washing liquid.
Background technology
Neonatal dacryocystitis is owing to the residual film of the embryo of nasolacrimal duct lower end is not degenerated, block nasolacrimal duct lower end, tear and
Antibacterial retention, in lachrymal sac, causes caused by secondary infection.Neonatal dacryocystitis is relatively common oculopathy, shows as baby's
Eyes are often tearful.Have many dense sexual secretions to flow out in the eyes of baby, age of onset can early can evening, have
Be birth after within first day, just have symptom, have can be general one week after or one month after occur.The long-term tear of neonate
Capsulitis, safety to eye is-serious threat.Progressive symmetric erythrokeratodermia corneal ulcer or eye penetrating wound, intraocular surgery etc. all can cause
Panophthalmitis.Corneal infection severe patient can cause perforation of cornea, blind.
The basic principle of modern treatment is to remove lachrymal sac focus of infection, sets up Endonasal drainage passage.When using Drug therapy, drip
Extruding emptying lachrymal sac endocrine before medicine, medicinal liquid just can be inhaled into lachrymal sac；So have to irrigation of lacrimal passage, the most just can be thorough
Remove purulence or mucus secretions, strengthen curative effect of medication.If the pressure flush through monthly 2 times is the most invalid, row lacrimal passage is needed to visit
Logical art, punctures thin film with probe, makes unobstructed lacrimal passage.By pressure flush or probing of lacrimal passage, the infant of 99% can be fully recovered.
Prior art is the most all to use normal saline flushing lachrymal sac, but the eye of children's is had certain by normal saline
Stimulation, in addition, effect that dacryocystisis is treated by normal saline without other auxiliary.So being badly in need of developing a kind of safety
Do not stimulate and can assist the irrigation of lacrimal passage liquid for the treatment of dacryocystisis.
Summary of the invention
Present invention solves the technical problem that and be to provide a kind of children's's dacryocystisis nursing irrigation of lacrimal passage liquid, including following matter
Amount percentage ratio component: 0.01-0.04% laevo-ornidazole, 0.1-0.5% antibacterial peptide, 0.01-0.03% L-Borneol,
0.05-0.1% aescine, 0.02-0.2% obacunone, 0.02-0.05% allantoin, 0.03-0.08% naringenin,
0.005-0.1% shikimic acid, 0.003-0.1% cryptoxanthine, 0.01-0.1% vitamin A, 0.03-0.06% surfactant,
Surplus is water for injection.
Optimum ratio is: 0.02-0.03% laevo-ornidazole, 0.2-0.4% antibacterial peptide, the left-handed dragon of 0.015-0.025%
Brain, 0.06-0.09% aescine, 0.06-0.16% obacunone, 0.03-0.04% allantoin, 0.04-0.07% naringenin,
0.015-0.09% shikimic acid, 0.023-0.08% cryptoxanthine, 0.03-0.08% vitamin A, 0.04-0.05% surface activity
Agent, surplus are water for injection.
Preferred proportioning is: 0.025% laevo-ornidazole, 0.3% antibacterial peptide, 0.02% L-Borneol, 0.075% 7
Leaf saponin, 0.11% obacunone, 0.035% allantoin, 0.055% naringenin, 0.0525% shikimic acid, 0.0535% hidden Huang
Element, 0.055% vitamin A, 0.045% surfactant, surplus are water for injection.
Further, described antibacterial peptide is polymyxin E, and has a broad antifungal spectrum has no side effect, and safety is high.
Further, described surfactant is polyoxyethylenesorbitan sorbitan monooleate.
Irrigation of lacrimal passage liquid is used in a kind of children's's dacryocystisis nursing, and its preparation method is:
Laevo-ornidazole, antibacterial peptide, L-Borneol, aescine, obacunone, allantoin, naringenin, big is weighed by formula
Oxalic acid, cryptoxanthine, vitamin A, surfactant, water for injection, add in vacuum emulsification homogenizer, 200-400r/min's
It is thoroughly mixed under speed conditions, then regulates pH to 5.0-5.5 by pH adjusting agent, be placed in ultrasonic disperse in ultrasonic disperse equipment
Process, stand froth breaking, obtain filtrate with filtering with microporous membrane, i.e. obtain children's's dacryocystisis nursing irrigation of lacrimal passage liquid.
Further, the aperture of described microporous filter membrane is 0.22-0.26 μm.
The invention has the beneficial effects as follows: children's's dacryocystisis nursing irrigation of lacrimal passage liquid phase of the present invention is for existing physiology
For normal saline washing liquid, there is antimicrobial antiphlogistic effect, enable in particular to control the infection caused by anaerobe, promote probing of lacrimal passage
Rear recovery, can protect neural activity simultaneously, to safeguarding that machine vision health has certain effect.
Detailed description of the invention
Embodiment 1:
A kind of children's's dacryocystisis nursing uses irrigation of lacrimal passage liquid, including the component of following mass percent: 0.01% left-handed Austria
Nitre azoles, 0.1% antibacterial peptide, 0.01% L-Borneol, 0.05% aescine, 0.02% obacunone, 0.02% allantoin,
0.03% naringenin, 0.005% shikimic acid, 0.003% cryptoxanthine, 0.01% vitamin A, 0.03% surfactant, surplus
For water for injection.
Wherein, described antibacterial peptide is polymyxin E, and has a broad antifungal spectrum has no side effect, and safety is high.Described surfactant
For polyoxyethylenesorbitan sorbitan monooleate.
The preparation method of this children's's dacryocystisis nursing irrigation of lacrimal passage liquid is:
Laevo-ornidazole, antibacterial peptide, L-Borneol, aescine, obacunone, allantoin, naringenin, big is weighed by formula
Oxalic acid, cryptoxanthine, vitamin A, surfactant, water for injection, add in vacuum emulsification homogenizer, at the rotating speed of 200r/min
Under the conditions of be thoroughly mixed, then regulate pH to 5.0 by pH adjusting agent, be placed in ultrasonic disperse equipment ultrasonic disperse and process, quiet
Putting froth breaking, obtain filtrate with filtering with microporous membrane, the aperture of described microporous filter membrane is 0.22 μm, i.e. obtains the nursing of children's's dacryocystisis and uses
Irrigation of lacrimal passage liquid.
Embodiment 2:
A kind of children's's dacryocystisis nursing uses irrigation of lacrimal passage liquid, including the component of following mass percent: 0.02% left-handed Austria
Nitre azoles, 0.2% antibacterial peptide, 0.015% L-Borneol, 0.06% aescine, 0.06% obacunone, 0.03% allantoin,
0.04% naringenin, 0.015% shikimic acid, 0.023% cryptoxanthine, 0.03% vitamin A, 0.04% surfactant, surplus
For water for injection.
Wherein, described antibacterial peptide is polymyxin E, and has a broad antifungal spectrum has no side effect, and safety is high.Described surfactant
For polyoxyethylenesorbitan sorbitan monooleate.
The preparation method of this children's's dacryocystisis nursing irrigation of lacrimal passage liquid is:
Laevo-ornidazole, antibacterial peptide, L-Borneol, aescine, obacunone, allantoin, naringenin, big is weighed by formula
Oxalic acid, cryptoxanthine, vitamin A, surfactant, water for injection, add in vacuum emulsification homogenizer, at the rotating speed of 250r/min
Under the conditions of be thoroughly mixed, then regulate pH to 5.0 by pH adjusting agent, be placed in ultrasonic disperse equipment ultrasonic disperse and process, quiet
Putting froth breaking, obtain filtrate with filtering with microporous membrane, the aperture of described microporous filter membrane is 0.23 μm, i.e. obtains the nursing of children's's dacryocystisis and uses
Irrigation of lacrimal passage liquid.
Embodiment 3:
A kind of children's's dacryocystisis nursing uses irrigation of lacrimal passage liquid, including the component of following mass percent: 0.025% left-handed Austria
Nitre azoles, 0.3% antibacterial peptide, 0.02% L-Borneol, 0.075% aescine, 0.11% obacunone, 0.035% allantoin,
0.055% naringenin, 0.0525% shikimic acid, 0.0535% cryptoxanthine, 0.055% vitamin A, 0.045% surfactant,
Surplus is water for injection.
Wherein, described antibacterial peptide is polymyxin E, and has a broad antifungal spectrum has no side effect, and safety is high.Described surfactant
For polyoxyethylenesorbitan sorbitan monooleate.
The preparation method of this children's's dacryocystisis nursing irrigation of lacrimal passage liquid is:
Laevo-ornidazole, antibacterial peptide, L-Borneol, aescine, obacunone, allantoin, naringenin, big is weighed by formula
Oxalic acid, cryptoxanthine, vitamin A, surfactant, water for injection, add in vacuum emulsification homogenizer, at the rotating speed of 300r/min
Under the conditions of be thoroughly mixed, then regulate pH to 5.2 by pH adjusting agent, be placed in ultrasonic disperse equipment ultrasonic disperse and process, quiet
Putting froth breaking, obtain filtrate with filtering with microporous membrane, the aperture of described microporous filter membrane is 0.24 μm, i.e. obtains the nursing of children's's dacryocystisis and uses
Irrigation of lacrimal passage liquid.
Embodiment 4:
A kind of children's's dacryocystisis nursing uses irrigation of lacrimal passage liquid, including the component of following mass percent: 0.03% left-handed Austria
Nitre azoles, 0.4% antibacterial peptide, 0.025% L-Borneol, 0.09% aescine, 0.16% obacunone, 0.04% allantoin,
0.07% naringenin, 0.09% shikimic acid, 0.08% cryptoxanthine, 0.08% vitamin A, 0.05% surfactant, surplus are
Water for injection.
Wherein, described antibacterial peptide is polymyxin E, and has a broad antifungal spectrum has no side effect, and safety is high.Described surfactant
For polyoxyethylenesorbitan sorbitan monooleate.
The preparation method of this children's's dacryocystisis nursing irrigation of lacrimal passage liquid is:
Laevo-ornidazole, antibacterial peptide, L-Borneol, aescine, obacunone, allantoin, naringenin, big is weighed by formula
Oxalic acid, cryptoxanthine, vitamin A, surfactant, water for injection, add in vacuum emulsification homogenizer, at the rotating speed of 350r/min
Under the conditions of be thoroughly mixed, then regulate pH to 5.5 by pH adjusting agent, be placed in ultrasonic disperse equipment ultrasonic disperse and process, quiet
Putting froth breaking, obtain filtrate with filtering with microporous membrane, the aperture of described microporous filter membrane is 0.25 μm, i.e. obtains the nursing of children's's dacryocystisis and uses
Irrigation of lacrimal passage liquid.
Embodiment 5:
A kind of children's's dacryocystisis nursing uses irrigation of lacrimal passage liquid, including the component of following mass percent: 0.04% left-handed Austria
Nitre azoles, 0.5% antibacterial peptide, 0.03% L-Borneol, 0.1% aescine, 0.2% obacunone, 0.05% allantoin, 0.08%
Naringenin, 0.1% shikimic acid, 0.1% cryptoxanthine, 0.1% vitamin A, 0.06% surfactant, surplus are water for injection.
Wherein, described antibacterial peptide is polymyxin E, and has a broad antifungal spectrum has no side effect, and safety is high.Described surfactant
For polyoxyethylenesorbitan sorbitan monooleate.
The preparation method of this children's's dacryocystisis nursing irrigation of lacrimal passage liquid is:
Laevo-ornidazole, antibacterial peptide, L-Borneol, aescine, obacunone, allantoin, naringenin, big is weighed by formula
Oxalic acid, cryptoxanthine, vitamin A, surfactant, water for injection, add in vacuum emulsification homogenizer, at the rotating speed of 400r/min
Under the conditions of be thoroughly mixed, then regulate pH to 5.5 by pH adjusting agent, be placed in ultrasonic disperse equipment ultrasonic disperse and process, quiet
Putting froth breaking, obtain filtrate with filtering with microporous membrane, the aperture of described microporous filter membrane is 0.26 μm, i.e. obtains the nursing of children's's dacryocystisis and uses
Irrigation of lacrimal passage liquid.
Clinical data:
Case selection: children's's dacryocystisis patient 156 example that my institute's department of pediatrics in May, 2012～in July, 2013 accept for medical treatment altogether, wherein
Man's 89 examples, female 67 example；Age between 1 week-20 months, 3.1 months mean aves；The course of disease between 3-14 days, average course of disease
8.2 my god；Infant is simple eye morbidity, wherein, left eye 62 example, right eye 94 example；Suffer from eye all have redness in various degree, shed tears, pus
The symptoms such as sexual secretion.Diagnose through clinician after being admitted to hospital, be all diagnosed as children's dacryocystisis patient.Infant is randomly divided into 4 groups,
The clinical datas such as the sex of 4 groups of infants, age, occurring degree, the course of disease are carried out statistical analysis, P=0.054 ＞ 0.05, number
According to not having the significance difference opposite sex.156 example infants are randomly divided into embodiment 1 treatment group, embodiment 2 treatment group and embodiment 5 control
Treatment group and matched group, each experimental group 77 people.
Embodiment 1 treatment group: use the flushing liquor of the embodiment of the present invention 1 preparation to carry out eye flushing, every day 1 time, every 7 days
It it is a course for the treatment of；Use 2 courses for the treatment of altogether.
Embodiment 2 treatment group: use the flushing liquor of the embodiment of the present invention 2 preparation to carry out eye flushing, every day 1 time, every 7 days
It it is a course for the treatment of；Use 2 courses for the treatment of altogether.
Embodiment 5 treatment group: use the flushing liquor of the embodiment of the present invention 5 preparation to carry out eye flushing, every day 1 time, every 7 days
It it is a course for the treatment of；Use 2 courses for the treatment of altogether.
Matched group: use normal saline conventional clinically: 0.85% sodium chloride aseptic aqueous solution carries out eye flushing, often
Day 1 time, every 7 days is a course for the treatment of；Use 2 courses for the treatment of altogether.
Touchstone:
(1) whether lachrymal sac endocrine empties；
(2) cure rate: the Therapeutic Method that all patients are used all as, the irrigation of lacrimal passage that the most different is exactly uses
Liquid is different.
Cure is added up:
| Group | Secretions emptying number/people | Emptying Rate/% | Healing number/people | Cure rate/% |
| Embodiment 1 | 32 | 82.05 | 31 | 79.48 |
| Embodiment 2 | 34 | 87.17 | 32 | 82.05 |
| Embodiment 5 | 37 | 94.87 | 36 | 92.31 |
| Matched group | 21 | 53.84 | 18 | 46.15 |
Result: from above-mentioned therapeutic outcome, the irrigation of lacrimal passage liquid phase of the present invention for general normal saline, eye
Secretions Emptying Rate is higher, and cure rate is the highest, and not only the purulent secretion to lacrimal passage has certain flushing action, and to tear
The recovery of capsulitis has certain assosting effect.
The foregoing is only the preferred embodiments of the present invention, be not limited to the present invention, for the skill of this area
For art personnel, the present invention can have various modifications and variations.All within the spirit and principles in the present invention, that is made any repaiies
Change, equivalent, improvement etc., should be included within the scope of the present invention.
Claims (7)
1. irrigation of lacrimal passage liquid is used in children's's dacryocystisis nursing, it is characterised in that include the component of following mass percent:
0.01-0.04% laevo-ornidazole, 0.1-0.5% antibacterial peptide, 0.01-0.03% L-Borneol, 0.05-0.1% aescine,
0.02-0.2% obacunone, 0.02-0.05% allantoin, 0.03-0.08% naringenin, 0.005-0.1% shikimic acid, 0.003-
0.1% cryptoxanthine, 0.01-0.1% vitamin A, 0.03-0.06% surfactant, surplus are water for injection.
2. irrigation of lacrimal passage liquid is used in a kind of children's's dacryocystisis nursing as claimed in claim 1, it is characterised in that include following quality
The component of percentage ratio: 0.02-0.03% laevo-ornidazole, 0.2-0.4% antibacterial peptide, 0.015-0.025% L-Borneol,
0.06-0.09% aescine, 0.06-0.16% obacunone, 0.03-0.04% allantoin, 0.04-0.07% naringenin,
0.015-0.09% shikimic acid, 0.023-0.08% cryptoxanthine, 0.03-0.08% vitamin A, 0.04-0.05% surface activity
Agent, surplus are water for injection.
3. irrigation of lacrimal passage liquid is used in a kind of children's's dacryocystisis nursing as claimed in claim 1, it is characterised in that include following quality
The component of percentage ratio: 0.025% laevo-ornidazole, 0.3% antibacterial peptide, 0.02% L-Borneol, 0.075% aescine,
0.11% obacunone, 0.035% allantoin, 0.055% naringenin, 0.0525% shikimic acid, 0.0535% cryptoxanthine,
0.055% vitamin A, 0.045% surfactant, surplus are water for injection.
4. irrigation of lacrimal passage liquid is used in a kind of children's's dacryocystisis nursing as claimed in claim 1, it is characterised in that described antibacterial peptide is
Polymyxin E.
5. irrigation of lacrimal passage liquid is used in a kind of children's's dacryocystisis nursing as claimed in claim 1, it is characterised in that described surface activity
Agent is polyoxyethylenesorbitan sorbitan monooleate.
6. a kind of children's's dacryocystisis nursing irrigation of lacrimal passage liquid as described in claim 1 to 5, it is characterised in that preparation method
For:
Laevo-ornidazole, antibacterial peptide, L-Borneol, aescine, obacunone, allantoin, naringenin, Folium illicii Lanceolati is weighed by formula
Acid, cryptoxanthine, vitamin A, surfactant, water for injection, add in vacuum emulsification homogenizer, turning at 200-400r/min
It is thoroughly mixed under the conditions of speed, stands froth breaking, obtain filtrate with filtering with microporous membrane, i.e. obtain children's's dacryocystisis nursing lacrimal passage
Flushing liquor.
7. irrigation of lacrimal passage liquid is used in a kind of children's's dacryocystisis nursing as claimed in claim 6, it is characterised in that described microporous filter membrane
Aperture be 0.22-0.26 μm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610703829.7A CN106267151A (en) | 2016-08-22 | 2016-08-22 | Irrigation of lacrimal passage liquid is used in a kind of children's's dacryocystisis nursing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610703829.7A CN106267151A (en) | 2016-08-22 | 2016-08-22 | Irrigation of lacrimal passage liquid is used in a kind of children's's dacryocystisis nursing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106267151A true CN106267151A (en) | 2017-01-04 |
Family
ID=57661265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610703829.7A Pending CN106267151A (en) | 2016-08-22 | 2016-08-22 | Irrigation of lacrimal passage liquid is used in a kind of children's's dacryocystisis nursing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106267151A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1459291A (en) * | 2003-05-28 | 2003-12-03 | 凌沛学 | Eyedrops containing low molecular weight heparin, and its prepn. method |
| CN101797332A (en) * | 2010-04-15 | 2010-08-11 | 滕淑玲 | Traditional Chinese medicine for treating chronic dacryocystitis and preparation method thereof |
| CN104189335A (en) * | 2014-09-02 | 2014-12-10 | 张会英 | Lacrimal passage flushing fluid for caring infantile dacryocystitis and preparation method thereof |
| CN105362533A (en) * | 2015-12-23 | 2016-03-02 | 许立华 | Nursing lacrimal passage flushing fluid for infantile dacryocystitis and preparation method of flushing fluid |
| CN105497732A (en) * | 2015-12-21 | 2016-04-20 | 许立华 | Lacrimal duct irrigation fluid for nursing of infantile congenital lacrimal duct obstruction |
-
2016
- 2016-08-22 CN CN201610703829.7A patent/CN106267151A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1459291A (en) * | 2003-05-28 | 2003-12-03 | 凌沛学 | Eyedrops containing low molecular weight heparin, and its prepn. method |
| CN101797332A (en) * | 2010-04-15 | 2010-08-11 | 滕淑玲 | Traditional Chinese medicine for treating chronic dacryocystitis and preparation method thereof |
| CN104189335A (en) * | 2014-09-02 | 2014-12-10 | 张会英 | Lacrimal passage flushing fluid for caring infantile dacryocystitis and preparation method thereof |
| CN105497732A (en) * | 2015-12-21 | 2016-04-20 | 许立华 | Lacrimal duct irrigation fluid for nursing of infantile congenital lacrimal duct obstruction |
| CN105362533A (en) * | 2015-12-23 | 2016-03-02 | 许立华 | Nursing lacrimal passage flushing fluid for infantile dacryocystitis and preparation method of flushing fluid |
Non-Patent Citations (4)
| Title |
|---|
| 林俊粒: "柚皮素滴眼液对光感受器细胞凋亡的防治作用及机制研究", 《中国优秀硕士学位论文全文数据库（医药卫生科技辑）》 * |
| 王 艳: "复方丹参联合七叶皂苷钠治疗外伤性眼底缺血性病变的观察", 《中国伤残医学》 * |
| 王瑞侠等: "小儿个性化泪道冲洗的观察与护理", 《当代医学》 * |
| 钟赣生: "《中药学》", 31 December 2012 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104435763B (en) | A kind of medicine for treating illness in eye | |
| CN109091675A (en) | A kind of compound low concentration atropic category medicament dropping ocular fluid and preparation method thereof | |
| CN109675038A (en) | Enhance the composition of low concentration atropic category drug safety and clinical efficacy | |
| CN109419770A (en) | A kind of mescenchymal stem cell excretion body eye drops and its preparation method and application | |
| CN111544390B (en) | Traditional Chinese medicine preparation for treating meibomian gland dysfunction and/or allergic conjunctivitis, ultrasonic atomization and nano-spray preparation and preparation method | |
| CN102362924B (en) | Medicinal composition for treating ophthalmic diseases and preparation method thereof | |
| CN101278908B (en) | Eye drop capable of significantly increasing medicament effect | |
| CN101284048A (en) | Formulations for effectively improving hypometropia, asthenopia, cataract, eyeground pathological changes | |
| Weinstein | Nervism in ophthalmology | |
| CN105106318A (en) | Traditional Chinese medicine composition for treating xerophthalmia and preparation method of traditional Chinese medicine composition | |
| CN106267151A (en) | Irrigation of lacrimal passage liquid is used in a kind of children's's dacryocystisis nursing | |
| CN104906220A (en) | Traditional Chinese medicine for treating herpes zoster and herpes simplex viral keratitis | |
| CN105012487A (en) | Bishutong nasal drops for children | |
| CN108066282B (en) | A kind of Levofloxacin Eye drop and preparation method thereof | |
| Davitt et al. | Endogenous Nocardia endophthalmitis | |
| CN105168237A (en) | Compound gel moisturizing eye drops | |
| CN105963319A (en) | Saturated hydrogen saline water washing liquor and preparation method and application thereof | |
| CN105902686A (en) | In-situ gel eyewash containing nano-carbon crystals and preparation method thereof | |
| CN103550357B (en) | A kind of control muscae volitantes collyrium and its production and use | |
| CN103860731A (en) | Pure traditional Chinese medicine preparation for treating eye disease | |
| RU2494735C1 (en) | Method of treating corneal ulcers | |
| CN105963677A (en) | Eye nursing gel and preparation method thereof | |
| CN114146108A (en) | Formula of eye drop and preparation method thereof | |
| Green | Notes of cases illustrating the use of adrenalin chloride in ophthalmic, nasal, and aural surgery | |
| LIU et al. | Traditional Chinese herbal medicine ultrasonic atomization combined with bloodletting at Ěrjiān (EX-HN 6) for acute catarrhal conjunctivitis: a randomized controlled trial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |
|
| RJ01 | Rejection of invention patent application after publication |